Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabis Oil for Pain in Parkinson's Disease
NCT03639064Phase 2Unknown
- Sponsor
- University Health Network
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabis oil in Parkinson's disease (PD) (3 arms), sponsored by University Health Network. Primary endpoints: Maximum Tolerated Dose at 35 days and Treatment-emergent adverse events at 35 days. Status: unknown.
02
Drugs
cannabis oil
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03639064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639064.